Multiple system atrophy: an update

Graham, 1969, Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy, J Neurol Neurosurg Psychiatry, 32, 28, 10.1136/jnnp.32.1.28 Papp, 1989, Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome), J Neurol Sci, 94, 79, 10.1016/0022-510X(89)90219-0 Spillantini, 1998, Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies, Neurosci Lett, 251, 205, 10.1016/S0304-3940(98)00504-7 Wakabayashi, 1998, Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy, Neurosci Lett, 249, 180, 10.1016/S0304-3940(98)00407-8 Beyer, 2007, Protein aggregation mechanisms in synucleinopathies: commonalities and differences, J Neuropathol Exp Neurol, 66, 965, 10.1097/nen.0b013e3181587d64 Gilman, 1998, Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology, Clin Auton Res, 8, 359, 10.1007/BF02309628 Wenning, 2004, Development and validation of the unified multiple system atrophy rating scale (UMSARS), Mov Disord, 19, 1391, 10.1002/mds.20255 Gilman, 2008, Second consensus statement on the diagnosis of multiple system atrophy, Neurology, 71, 670, 10.1212/01.wnl.0000324625.00404.15 Bower, 1997, Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990, Neurology, 49, 1284, 10.1212/WNL.49.5.1284 Wenning, 2004, Multiple system atrophy, Lancet Neurol, 3, 93, 10.1016/S1474-4422(03)00662-8 Wullner, 2007, Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease, J Neural Transm, 114, 1161, 10.1007/s00702-007-0746-0 Schrag, 2008, Survival in multiple system atrophy, Mov Disord, 23, 294, 10.1002/mds.21839 Geser, 2006, Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG), Mov Disord, 21, 179, 10.1002/mds.20678 May, 2007, Potential outcome measures and trial design issues for multiple system atrophy, Mov Disord, 22, 2371, 10.1002/mds.21734 Yabe, 2006, MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA, J Neurol Sci, 249, 115, 10.1016/j.jns.2006.05.064 Seppi, 2005, Progression of parkinsonism in multiple system atrophy, J Neurol, 252, 91, 10.1007/s00415-005-0617-2 Seppi, 2006, Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study, Neuroimage, 31, 240, 10.1016/j.neuroimage.2005.12.006 Brenneis, 2007, Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study, J Neurol, 254, 191, 10.1007/s00415-006-0325-6 Kollensperger, 2007, Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment, Eur J Neurol, 14, 66, 10.1111/j.1468-1331.2006.01554.x Tada, 2007, Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy, Arch Neurol, 64, 256, 10.1001/archneur.64.2.256 O'Sullivan, 2008, Clinical outcomes of progressive supranuclear palsy and multiple system atrophy, Brain, 131, 1362, 10.1093/brain/awn065 Geser, 2005, The European Multiple System Atrophy-Study Group (EMSA-SG), J Neural Transm, 112, 1677, 10.1007/s00702-005-0328-y Stampfer-Kountchev, 2005, Evaluation of diagnostic and therapeutic standards for MSA in Europe: first results from the European MSA Registry (EMSA-R), Mov Disord, 20, S144 Trojanowski, 2007, Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy, Neuropathol Appl Neurobiol, 33, 615, 10.1111/j.1365-2990.2007.00907.x Orimo, 2008, Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease, Brain, 131, 642, 10.1093/brain/awm302 Mitsui, 2006, Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease, J Neurol Sci, 243, 101, 10.1016/j.jns.2005.11.034 Miyamoto, 2008, 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder, Sleep, 31, 717, 10.1093/sleep/31.5.717 Chung, 2009, MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy, Mov Disord, 24, 1650, 10.1002/mds.22649 Brooks, 2009, Proposed neuroimaging criteria for the diagnosis of multiple system atrophy, Mov Disord, 24, 949, 10.1002/mds.22413 Ozawa, 2004, The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations, Brain, 127, 2657, 10.1093/brain/awh303 Jellinger, 2005, Grading of neuropathology in multiple system atrophy: proposal for a novel scale, Mov Disord, 20, S29, 10.1002/mds.20537 Orosz, 2004, TPPP/p25: from unfolded protein to misfolding disease: prediction and experiments, Biol Cell, 96, 701, 10.1016/j.biolcel.2004.08.002 Song, 2007, p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy, Am J Pathol, 171, 1291, 10.2353/ajpath.2007.070201 Lindersson, 2005, p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies, J Biol Chem, 280, 5703, 10.1074/jbc.M410409200 Wenning, 2008, Multiple system atrophy: a primary oligodendrogliopathy, Ann Neurol, 64, 239, 10.1002/ana.21465 Yoshida, 2007, Multiple system atrophy: alpha-synuclein and neuronal degeneration, Neuropathology, 27, 484, 10.1111/j.1440-1789.2007.00841.x Trojanowski, 2007, Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy, Neuropathol Appl Neurobiol, 33, 615, 10.1111/j.1365-2990.2007.00907.x Wakabayashi, 2005, An autopsy case of early (“minimal change”) olivopontocerebellar atrophy (multiple system atrophy-cerebellar), Acta Neuropathol, 110, 185, 10.1007/s00401-005-1029-1 Nishie, 2004, A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy, Neuropathol Appl Neurobiol, 30, 546, 10.1111/j.1365-2990.2004.00564.x Baker, 2006, p25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy, Acta Neuropathol, 111, 193, 10.1007/s00401-005-0008-x Soma, 2006, Heredity in multiple system atrophy, J Neurol Sci, 240, 107, 10.1016/j.jns.2005.09.003 Wullner, 2009, Definite multiple system atrophy in a German family, J Neurol Neurosurg Psychiatry, 80, 449, 10.1136/jnnp.2008.158949 Scholz, 2009, SNCA variants are associated with increased risk for multiple system atrophy, Ann Neurol, 65, 610, 10.1002/ana.21685 Al-Chalabi, 2009, Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy, PLoS One, 4, e7114, 10.1371/journal.pone.0007114 Vanacore, 2005, Epidemiological evidence on multiple system atrophy, J Neural Transm, 112, 1605, 10.1007/s00702-005-0380-7 Vidal, 2008, Risk factors of multiple system atrophy: a case-control study in French patients, Mov Disord, 23, 797, 10.1002/mds.21857 Yazawa, 2005, Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration, Neuron, 45, 847, 10.1016/j.neuron.2005.01.032 Shults, 2005, Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy, J Neurosci, 25, 10689, 10.1523/JNEUROSCI.3527-05.2005 Stefanova, 2007, Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy, Mov Disord, 22, 2196, 10.1002/mds.21671 Stefanova, 2005, Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy, Am J Pathol, 166, 869, 10.1016/S0002-9440(10)62307-3 Ubhi, 2009, Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy, J Neurosci Res, 87, 2728, 10.1002/jnr.22089 Wenning, 2009, Recent developments in multiple system atrophy, J Neurol, 256, 1791, 10.1007/s00415-009-5173-8 Holmberg, 2007, Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study, Mov Disord, 22, 1138, 10.1002/mds.21501 Bensimon, 2009, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study, Brain, 132, 156, 10.1093/brain/awn291 Olanow, 2008, A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics, Mov Disord, 23, 2194, 10.1002/mds.22218 Poewe, 2009, Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson's disease: assessment with the revised MDS-UPDRAS, Mov Disord, 24, S272 Rascol, 2009, The effect of rasagiline in early Parkinson's disease (PD): the ADAGIO delayed start trial, Mov Disord, 24, S275 Stocchi, 2009, Rasagiline provides benefits in the symptoms of fatigue in patients with early Parkinson's disease, Mov Disord, 24, S280 Olanow, 2009, A double-blind, delayed-start trial of rasagiline in Parkinson's disease, N Engl J Med, 361, 1268, 10.1056/NEJMoa0809335 Stefanova, 2008, Rasagiline is neuroprotective in a transgenic model of multiple system atrophy, Exp Neurol, 210, 421, 10.1016/j.expneurol.2007.11.022 Li, 2004, Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils, Chem Biol, 11, 1513, 10.1016/j.chembiol.2004.08.025 Ubhi, 2008, Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy, Neuroreport, 19, 1271, 10.1097/WNR.0b013e32830b3661 Stefanova, 2005, Animal models of multiple system atrophy, Trends Neurosci, 28, 501, 10.1016/j.tins.2005.07.002 Stefanova, 2009, Striatal transplantation for multiple system atrophy: are grafts affected by alpha-synucleinopathy?, Exp Neurol, 219, 368, 10.1016/j.expneurol.2009.05.016 Lee, 2008, Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy, Clin Pharmacol Ther, 83, 723, 10.1038/sj.clpt.6100386